Just reported
Q3 2026 results
From Adaptive Biotechnologies Corporation's results release of November 4, 2026; its quarterly report has since been filed.
Revenue
Actual
$83.9M
-11% y/y ↓
+17% q/q ↑
EPS, GAAP
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $83.9M | $94M | -10.72% |
| Profit | $2.9M | $9.5M | -69.87% |
| Profit per share | $0.02 | $0.06 | -66.67% |
| Free Cash Flow | $7.7M | -$7.5M | +201.86% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingAdaptive Biotechnologies Corporation reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$25.80
Nov 3, 2026
Close after
$26.83
Nov 5, 2026
Move
+3.99%
4.05M shares traded, against a normal 2.15M
What Adaptive Biotechnologies Corporation does
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Adaptive Biotechnologies Corporation’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
